232 related articles for article (PubMed ID: 37000975)
1. Clinical pharmacological innovation in the treatment of depression.
Witkin JM; Golani LK; Smith JL
Expert Rev Clin Pharmacol; 2023 Apr; 16(4):349-362. PubMed ID: 37000975
[TBL] [Abstract][Full Text] [Related]
2. Where do we go next in antidepressant drug discovery? A new generation of antidepressants: a pivotal role of AMPA receptor potentiation and mGlu2/3 receptor antagonism.
Pilc A; Machaczka A; Kawalec P; Smith JL; Witkin JM
Expert Opin Drug Discov; 2022 Oct; 17(10):1131-1146. PubMed ID: 35934973
[TBL] [Abstract][Full Text] [Related]
3. Rapid-Acting Antidepressants.
Witkin JM; Knutson DE; Rodriguez GJ; Shi S
Curr Pharm Des; 2018; 24(22):2556-2563. PubMed ID: 30058481
[TBL] [Abstract][Full Text] [Related]
4. Rapid-acting antidepressants.
Witkin JM; Martin AE; Golani LK; Xu NZ; Smith JL
Adv Pharmacol; 2019; 86():47-96. PubMed ID: 31378256
[TBL] [Abstract][Full Text] [Related]
5. mGlu2/3 receptor antagonists for depression: overview of underlying mechanisms and clinical development.
Chaki S; Watanabe M
Eur Arch Psychiatry Clin Neurosci; 2023 Oct; 273(7):1451-1462. PubMed ID: 36715750
[TBL] [Abstract][Full Text] [Related]
6. New investigational agents for the treatment of major depressive disorder.
Pochwat B; Krupa AJ; Siwek M; Szewczyk B
Expert Opin Investig Drugs; 2022 Oct; 31(10):1053-1066. PubMed ID: 35975761
[TBL] [Abstract][Full Text] [Related]
7. [Contribution of serotonin 5-HT
Ibi D
Nihon Yakurigaku Zasshi; 2023 May; 158(3):229-232. PubMed ID: 36990794
[TBL] [Abstract][Full Text] [Related]
8. An update on NMDA antagonists in depression.
Pochwat B; Nowak G; Szewczyk B
Expert Rev Neurother; 2019 Nov; 19(11):1055-1067. PubMed ID: 31328587
[No Abstract] [Full Text] [Related]
9. Interaction of hallucinogenic rapid-acting antidepressants with mGlu2/3 receptor ligands as a window for more effective therapies.
Chruścicka-Smaga B; Machaczka A; Szewczyk B; Pilc A
Pharmacol Rep; 2023 Dec; 75(6):1341-1349. PubMed ID: 37932583
[TBL] [Abstract][Full Text] [Related]
10. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms of rapid-acting antidepressants: New perspectives for developing antidepressants.
Chen T; Cheng L; Ma J; Yuan J; Pi C; Xiong L; Chen J; Liu H; Tang J; Zhong Y; Zhang X; Liu Z; Zuo Y; Shen H; Wei Y; Zhao L
Pharmacol Res; 2023 Aug; 194():106837. PubMed ID: 37379962
[TBL] [Abstract][Full Text] [Related]
12. Ketamine for Depression: Advances in Clinical Treatment, Rapid Antidepressant Mechanisms of Action, and a Contrast with Serotonergic Psychedelics.
Kojic M; Saelens J; Kadriu B; Zarate CA; Kraus C
Curr Top Behav Neurosci; 2022; 56():141-167. PubMed ID: 35312993
[TBL] [Abstract][Full Text] [Related]
13. mGlu2/3 receptor as a novel target for rapid acting antidepressants.
Chaki S
Adv Pharmacol; 2020; 89():289-309. PubMed ID: 32616210
[TBL] [Abstract][Full Text] [Related]
14. Emerging drugs for major depressive disorder.
Connolly KR; Thase ME
Expert Opin Emerg Drugs; 2012 Mar; 17(1):105-26. PubMed ID: 22339643
[TBL] [Abstract][Full Text] [Related]
15. Role of Serotonergic System in the Antidepressant Actions of mGlu2/3 Receptor Antagonists: Similarity to Ketamine.
Chaki S; Fukumoto K
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30871246
[TBL] [Abstract][Full Text] [Related]
16. Next generation antidepressants with novel mechanisms for treatment resistant depression.
Chen MH; Tu PC; Su TP
Prog Brain Res; 2023; 278():149-168. PubMed ID: 37414491
[TBL] [Abstract][Full Text] [Related]
17. NMDA antagonists under investigation for the treatment of major depressive disorder.
Pochwat B; Pałucha-Poniewiera A; Szewczyk B; Pilc A; Nowak G
Expert Opin Investig Drugs; 2014 Sep; 23(9):1181-92. PubMed ID: 24818801
[TBL] [Abstract][Full Text] [Related]
18. Targeting metabotropic glutamate receptors for rapid-acting antidepressant drug discovery.
Musazzi L
Expert Opin Drug Discov; 2021 Feb; 16(2):147-157. PubMed ID: 32962432
[TBL] [Abstract][Full Text] [Related]
19. Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder.
Niciu MJ; Ionescu DF; Richards EM; Zarate CA
J Neural Transm (Vienna); 2014 Aug; 121(8):907-24. PubMed ID: 24318540
[TBL] [Abstract][Full Text] [Related]
20. Role of group II metabotropic glutamate receptors in ketamine's antidepressant actions.
Onisiforou A; Georgiou P; Zanos P
Pharmacol Biochem Behav; 2023 Feb; 223():173531. PubMed ID: 36841543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
